# Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

> **NCT00052689** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 88 (estimated)

## Conditions studied

- Duct Cell Adenocarcinoma of the Pancreas
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** bortezomib
- **DRUG:** gemcitabine hydrochloride

## Key facts

- **NCT ID:** NCT00052689
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2007-10
- **Final completion:** —
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2013-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00052689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00052689, "Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00052689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*